After sputtering on the launch pad, Novavax finally gets its EUA application in. Does it matter?
Novavax has finally met one of its self-imposed deadlines for the long-awaited EUA filing for its Covid-19 vaccine.
After repeatedly disappointing investors while raising questions about its ability to manufacture the vaccine to FDA standards, Novavax announced late Monday that the EUA has finally been dispatched to the agency.
For Novavax, the pandemic has been a godsend, offering the biotech a shot at its first approval — and this for what has been an enormous new market. But while Novavax floundered repeatedly at the FDA, Pfizer/BioNTech and Moderna — which yesterday followed up with their formal approval — cruised ahead with 2 new mRNA vaccines that have dominated the US market, with J&J’s one shot jab in the mix.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,300+ biopharma pros reading Endpoints daily — and it's free.